摘要
血脂异常是动脉粥样硬化性心血管疾病的最主要危险因素之一。近年来降脂药物的研究不断取得新进展,他汀类药物、胆固醇吸收抑制剂、前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂和ω-3脂肪酸得到了广泛的应用,血管生成素样蛋白3(ANGPTL3)抑制剂、载脂蛋白C3(Apo C3)抑制剂、单克隆抗体、反义寡核苷酸(ASOs)、小分子干扰RNA(siRNA)和胆固醇疫苗的研究使得新型降脂药的形式变得多样化,且呈现出潜在的良好疗效。本文对于降脂治疗药物的应用及研发进行综述,为降脂治疗提供新思路。
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular diseases.Recent advancements in lipid-lowering therapies have seen progress with statins,cholesterol absorption inhibitors,PCSK9 inhibitors,and omega-3 fatty acids becoming widely utilized.Emerging new lipid-lowering drugs,including angiopoietin-like protein 3(ANGPTL3)inhibitors,apolipoprotein C3 inhibitors,monoclonal antibodies,antisense oligonucleotides(ASOs),small interfering RNA(siRNA),and cholesterol vaccines,have diversified the therapeutic landscape,showing promising efficacy.This review explores the development and application of these lipid-lowering drugs,offering new insights for therapeutic strategies.
作者
胡鑫
王晓明
Hu Xin;Wang Xiaoming(Department of Geriatrics,Xijing Hospital,Air Force Medical University,Xi'an 710000;Medical School of Yan'an University,Yan'an 716000)
出处
《国际老年医学杂志》
2024年第5期601-605,共5页
International Journal of Geriatrics
基金
军队保健专项科研课题(23BJZ13)。
关键词
血脂异常
新型降脂药物
降脂治疗
Dyslipidemia
New lipid-lowering drugs
Lipid-lowering therapy